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Evaluating complex interventions is 
complicated. The Medical Research Council’s  
evaluation framework (2000) brought 
welcome clarity to the task. Now the council 
has  updated its guidance
Complex interventions are widely used in the health 
service, in public health practice, and in areas of social 
policy that have important health consequences, such 
as education, transport, and housing. They present 
various problems for evaluators, in addition to the 
practical and methodological difficulties that any suc-
cessful evaluation must overcome. In 2000, the Medical 
Research Council (MRC) published a framework1 to 
help researchers and research funders to recognise and 
adopt appropriate methods. The framework has been 
highly influential, and the accompanying BMJ paper 
is widely cited.2 However, much valuable experience 
has since accumulated of both conventional and more 
innovative methods. This has now been incorporated 
in comprehensively revised and updated guidance 
recently released by the MRC (www.mrc.ac.uk/com-
plexinterventionsguidance). In this article we summa-
rise the issues that prompted the revision and the key 
messages of the new guidance.
revisiting the 2000 mrc framework
As experience of evaluating complex interventions 
has accumulated since the 2000 framework was pub-
lished, interest in the methodology has also grown. 
Several recent papers have identified limitations in the 
framework, recommending, for example, greater atten-
tion to early phase piloting and development work,3 
a less linear model of evaluation process,4 integration 
of process and outcome evaluation,5 recognition that 
complex interventions may work best if they are tai-
lored to local contexts rather than completely stand-
ardised,6 and greater use of the insights provided by 
the theory of complex adaptive systems.7 
A workshop held by the MRC Population Health 
Sciences Research Network to consider whether and 
how the framework should be updated likewise rec-
ommended the inclusion of a model of the evaluation 
process less closely tied to the phases of drug develop-
ment; more guidance on how to approach the devel-
opment, reporting, and implementation of complex 
interventions; and greater attention to the contexts 
in which interventions take place. It further recom-
mended consideration of alternatives to randomised 
trials, and of highly complex or non-health sector 
interventions to which biomedical methods may not 
be applicable, and more evidence and examples to 
back up and illustrate the recommendations. The new 
guidance addresses these issues in depth, and here we 
set out the key messages.
What are complex interventions?
Complex interventions are usually described as inter-
ventions that contain several interacting components, 
but they have other characteristics that evaluators 
should take into account (box 1). There is no sharp 
boundary between simple and complex interventions. 
Few interventions are truly simple, but the number 
of components and range of effects may vary widely. 
summary points
The Medical Research Council guidance for the evaluation 
of complex interventions has been revised and updated
The process of developing and evaluating a complex 
intervention has several phases, although they may not 
follow a linear sequence
Experimental designs are preferred to observational 
designs in most circumstances, but are not always 
practicable 
Understanding processes is important but does not replace 
evaluation of outcomes
Complex interventions may work best if tailored to local 
circumstances rather than being completely standardised 
Reports of studies should include a detailed description of 
the intervention to enable replication, evidence synthesis, 
and wider implementation
Box 1 | What makes an intervention complex?
Number of interacting components within the •	
experimental and control interventions
Number and difficulty of behaviours required by those •	
delivering or receiving the intervention
Number of groups or organisational levels targeted by the •	
intervention
Number and variability of outcomes•	
Degree of flexibility or tailoring of the intervention •	
permitted
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Some highly complex interventions, such as the Sure 
Start intervention to support families with young chil-
dren in deprived communities,8 may comprise a set of 
individually complex interventions.
How these characteristics are dealt with will depend 
on the aims of the evaluation. A key question in evaluat-
ing complex interventions is whether they are effective 
in everyday practice (box 2).9 It is therefore important 
to understand the whole range of effects and how they 
vary, for example, among recipients or between sites. 
A second key question in evaluating complex interven-
tions is how the intervention works: what are the active 
ingredients and how are they exerting their effect? 
Answers to this kind of question are needed to design 
more effective interventions and apply them appropri-
ately across group and setting.10
development, evaluation, and implementation 
The 2000 framework characterised the process of 
development through to implementation of a complex 
intervention in terms of the phases of drug develop-
ment. Although it is useful to think in terms of phases, 
in practice these may not follow a linear or even a 
cyclical sequence (figure).4
Best practice is to develop interventions systemati-
cally, using the best available evidence and appropri-
ate theory, then to test them using a carefully phased 
approach, starting with a series of pilot studies targeted 
at each of the key uncertainties in the design, and mov-
ing on to an exploratory and then a definitive evalua-
tion. The results should be disseminated as widely and 
persuasively as possible, with further research to assist 
and monitor the process of implementation.
In practice, evaluation takes place in a wide range 
of settings that constrain researchers’ choice of inter-
ventions to evaluate and their choice of evaluation 
methods. Ideas for complex interventions emerge 
from various sources, which may greatly affect how 
much leeway the researcher has to modify the inter-
vention, to influence the way it is implemented, or to 
adopt an ideal evaluation design.8 Evaluation may take 
place alongside large scale implementation, rather than 
starting beforehand. Strong evidence may be ignored 
or weak evidence taken up, depending on its politi-
cal acceptability or fit with other ideas about what 
works.11
Researchers need to consider carefully the trade-off 
between the importance of the intervention and the 
value of the evidence that can be gathered given these 
constraints. In an evaluation of the health impact of a 
social intervention, such as a programme of housing 
improvement, the researcher may have no say in what 
the intervention consists of and little influence over 
how or when the programme is implemented, limiting 
the scope to undertake development work or to deter-
mine allocation. Experimental methods are becoming 
more widely accepted as methods to evaluate policy,12 
but there may be political or ethical objections to using 
them to assess health effects, especially if the interven-
tion provides important non-health benefits.13 Given 
the cost of such interventions, evaluation should still 
be considered—the best available methods, even if they 
are not optimal in terms of internal validity, may yield 
useful results.14
If non-experimental methods are used, research-
ers should be aware of their limitations and interpret 
and present the findings with due caution. Wherever 
possible, evidence should be combined from differ-
ent sources that do not share the same weaknesses.15 
Researchers should be prepared to explain to decision 
makers the need for adequate development work, the 
pros and cons of experimental and non-experimental 
approaches, and the trade-offs involved in settling for 
weaker methods. They should be prepared to chal-
lenge decision makers when interventions of uncer-
tain effectiveness are being implemented in a way 
that would make strengthening the evidence through 
a rigorous evaluation difficult, or when a modification 
of the implementation strategy would open up the pos-
sibility of a much more informative evaluation.
developing a complex intervention
Identifying existing evidence—Before a substantial evalua-
tion is undertaken, the intervention must be developed 
to the point where it can reasonably be expected to 
have a worthwhile effect. The first step is to identify 
what is already known about similar interventions and 
the methods that have been used to evaluate them. If 
there is no recent, high quality systematic review of 
Box 2 |  Developing and evaluating complex studies
A good theoretical understanding is needed of how the •	
intervention causes change, so that weak links in the 
causal chain can be identified and strengthened
Lack of effect may reflect implementation failure (or •	
teething problems) rather than genuine ineffectiveness; 
a thorough process evaluation is needed to identify 
implementation problems
Variability in individual level outcomes may reflect •	
higher level processes; sample sizes may need to be 
larger to take account of the extra variability and cluster 
randomised designs considered
A single primary outcome may not make best use of the •	
data; a range of measures will be needed and unintended 
consequences picked up where possible
Ensuring strict standardisation may be inappropriate; •	
the intervention may work better if a specified degree of 
adaptation to local settings is allowed for in the protocol
Fig 1 |  Key elements of the development and evaluation process
Feasibility and piloting
Testing procedures
Estimating recruitment and retention
Determining sample size
Implementation
Dissemination
Surveillance and monitoring
Long term follow-up
Evaluation
Assessing effectiveness
Understanding change process
Assessing cost effectiveness
Development
Identifying the evidence base
Identifying or developing theory
Modelling process and outcomes
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the relevant evidence, one should be conducted and 
updated as the evaluation proceeds.
Identifying and developing theory—The rationale for a com-
plex intervention, the changes that are expected, and 
how change is to be achieved may not be clear at the 
outset. A key early task is to develop a theoretical under-
standing of the likely process of change by drawing on 
existing evidence and theory, supplemented if necessary 
by new primary research. This should be done whether 
the researcher is developing the intervention or evaluat-
ing one that has already been  developed.
Modelling process and outcomes—Modelling a complex 
intervention before a full scale evaluation can provide 
important information about the design of both the 
intervention and the evaluation. A series of studies 
may be required to progressively refine the design 
before embarking on a full scale  evaluation. Devel-
opers of a trial of physical activity to  prevent type 2 
diabetes adopted a causal modelling approach that 
included a range of  primary and desk based studies 
to design the intervention, identify suitable measures, 
and predict long term outcomes.3 Another useful 
approach is a prior  economic  evaluation.16 This may 
identify  weaknesses and lead to refinements, or even 
show that a full scale evaluation is unwarranted. A 
modelling exercise to prepare for a trial of falls pre-
vention in elderly people showed that the proposed 
system of screening and referral was highly unlikely 
to be cost effective and informed the decision not to 
proceed with the trial.17
assessing feasibility
Evaluations are often undermined by problems of 
acceptability, compliance, delivery of the intervention, 
recruitment and retention, and smaller than expected 
effect sizes that could have been predicted by thor-
ough piloting.18 A feasibility study for an evaluation 
of an adolescent sexual health intervention in rural 
Zimbabwe found that the planned classroom based 
programme was inappropriate, given cultural norms, 
teaching styles, and relationships between teachers 
and pupils in the country, and it was replaced by a 
community based programme.19 As well as illustrat-
ing the value of feasibility testing, the example shows 
the importance of understanding the context in which 
interventions take place.
A pilot study need not be a scale model of the 
planned evaluation but should examine the key uncer-
tainties that have been identified during development. 
Pilot studies for a trial of free home insulation suggested 
that attrition might be high, so the design was amended 
such that participants in the control group received the 
intervention after the study.20 Pilot study results should 
be interpreted cautiously when making assumptions 
about the numbers required when the evaluation is 
scaled up. Effects may be smaller or more variable and 
response rates lower when the intervention is rolled out 
across a wider range of settings.
evaluating a complex intervention
There are many study designs to choose from, and 
different designs suit different questions and circum-
stances. Researchers should beware of blanket state-
ments about what designs are suitable for what kind of 
intervention and choose on the basis of specific char-
acteristics of the study, such as expected effect size and 
likelihood of selection or allocation bias. Awareness of 
the whole range of experimental and non-experimental 
approaches should lead to more appropriate methodo-
logical choices.
Assessing effectiveness
Randomisation should always be considered because 
it is the most robust method of preventing selection 
bias. If a conventional parallel group randomised trial 
is not appropriate, other randomised designs should be 
considered (box 3).
If an experimental approach is not feasible, because 
the intervention is irreversible, necessarily applies to 
the whole population, or because large scale imple-
mentation is already under way, a quasi-experimental 
or an observational design may be considered. In some 
circumstances, randomisation may be unnecessary and 
Box 3 | Experimental designs for evaluating complex 
interventions
Individually randomised trials•	 —Individuals are randomly 
allocated to receive either an experimental intervention 
or an alternative such as standard treatment, a placebo, 
or remaining on a waiting list. Such trials are sometimes 
dismissed as inapplicable to complex interventions, but 
there are many variants, and often solutions can be found 
to the technical and ethical problems associated with 
randomisation
Cluster randomised trials•	  are one solution to the problem 
of contamination of the control group, leading to biased 
estimates of effect size, in trials of population level 
interventions. Groups such as patients in a general practice 
or tenants in a housing scheme are randomly allocated to 
the experimental or control intervention
Stepped wedge designs •	 may be used to overcome 
practical or ethical objections to experimentally evaluating 
an intervention for which there is some evidence of 
effectiveness or which cannot be made available to the 
whole population at once. It allows a trial to be conducted 
without delaying roll-out of the intervention. Eventually, 
the whole population receives the intervention, but with 
randomisation built into the phasing of implementation
Preference trials and randomised consent designs•	 —
Practical or ethical obstacles to randomisation can 
sometimes be overcome by using non-standard designs. 
When patients have strong preferences among treatments, 
basing treatment allocation on patients’ preferences or 
randomising patients before seeking consent may be 
appropriate.
N of 1 designs•	 —Conventional trials aim to estimate 
the average effect of an intervention in a population. N 
of 1 trials, in which individuals undergo interventions 
with the order or scheduling decided at random, can be 
used to assess between and within person change and 
to investigate theoretically predicted mediators of that 
change
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other designs preferable,21 22 but the conditions under 
which observational methods can yield reliable esti-
mates of effect are limited (box 4).23 Successful exam-
ples, such as the evaluation of legislation to restrict 
access to means of suicide,24 reduce air pollution,25 or 
ban smoking in public places,26 tend to occur where 
interventions have rapid, large effects.
Measuring outcomes
Researchers need to decide which outcomes are most 
important, which are secondary, and how they will 
deal with multiple outcomes in the analysis. A single 
primary outcome and a small number of secondary 
outcomes are the most straightforward for statistical 
analysis but may not represent the best use of the data 
or provide an adequate assessment of the success or 
otherwise of an intervention that has effects across a 
range of domains. It is important also to consider which 
sources of variation in outcomes matter and to plan 
appropriate subgroup analyses. 
Long term follow-up may be needed to determine 
whether outcomes predicted by interim or surrogate 
measures do occur or whether short term changes per-
sist. Although uncommon, such studies can be highly 
informative. Evaluation of a preschool programme 
for disadvantaged children showed that, as well as 
improved educational attainment, there was a range of 
economic and social benefits at ages 27 and 40.27
understanding processes
Process evaluations, which explore the way in which 
the intervention under study is implemented, can 
provide valuable insight into why an intervention 
fails or has unexpected consequences, or why a 
successful intervention works and how it can be 
optimised. A process evaluation nested inside a 
trial can be used to assess fidelity and quality of 
implementation, clarify causal mechanisms, and 
identify contextual factors associated with varia-
tion in outcomes.5 However, it is not a substitute 
for evaluation of outcomes. A process evaluation28 
carried out in connection with a trial of educational 
visits to encourage general practitioners to follow 
prescribing guidelines29 found that the visits were 
well received and recall of the guidelines was good, 
yet there was little change in prescribing behav-
iour, which was constrained by other factors such as 
patients’ preferences and local hospital policy.
Fidelity is not straightforward in relation to com-
plex interventions.30 In some evaluations, such as 
those seeking to identify active ingredients within 
a complex intervention, strict standardisation may 
be required and controls put in place to limit vari-
ation in implementation.31 But some interventions 
are designed to be adapted to local circumstances. 
In a trial of a school based intervention to promote 
health and wellbeing, schools were encouraged to 
use a standardised process to develop strategies 
which suited them rather than adopt a fixed cur-
riculum, resulting in widely varied practice between 
schools.32 The key is to be clear about how much 
change or adaptation is permissible and to record 
variations in implementation so that fidelity can be 
assessed in relation to the degree of standardisation 
required by the study protocol.
Variability in implementation, preplanned or 
otherwise, makes it important that both process 
and outcome evaluations are reported fully and 
that a clear description of the intervention is pro-
vided to enable replication and synthesis of evi-
dence.33 This has been a weakness of the reporting 
of complex intervention studies in the past,34 but 
the availability of a comprehensive range of report-
ing guidelines, now covering non-drug trials35 and 
observational studies36 and accessible through a sin-
gle website (www.equator-network.org) should lead 
to  improvement.
conclusions
We recognise that many issues surrounding evalua-
tion of complex interventions are still debated, that 
methods will continue to develop, and that practical 
applications will be found for some of the newer 
theories. We do not intend the revised guidance 
to be prescriptive but to help researchers, funders, 
and other decision makers to make appropriate 
methodological and practical choices. We have 
primarily aimed our messages at researchers, but 
publishers, funders, and commissioners of research 
also have an important part to play. Journal editors 
should insist on high and consistent standards of 
reporting. Research funders should be prepared to 
support developmental studies before large scale 
Box 4 | Choosing between randomised and  
non-randomised designs
Size and timing of effects—Randomisation may be 
unnecessary if the effects of the intervention are so large 
or immediate that confounding or underlying trends are 
unlikely to explain differences in outcomes before and 
after exposure. It may be inappropriate—for example, on 
grounds of cost or delay—if the changes are very small 
or take a long time to appear. In these circumstances a 
non-randomised design may be the only feasible option, 
in which case firm conclusions about the impact of the 
intervention may be unattainable
Likelihood of selection bias—Randomisation is needed if 
exposure to the intervention is likely to be associated with 
other factors that influence outcomes. Post-hoc adjustment 
is a second best solution; its effectiveness is limited by 
errors in the measurement of the confounding variables 
and the difficulty of dealing with unknown or unmeasured 
confounders
Feasibility and acceptability of experimentation—
Randomisation may be impractical if the intervention is 
already in widespread use, or if key decisions about how it 
will be implemented have already been taken, as is often 
the case with policy changes and interventions whose 
effect on health is secondary to their main purpose
Cost—If an experimental study is feasible and would 
provide more reliable information than an observational 
study but would also cost more, the additional cost should 
be weighed against the value of having better information
research methods & reporting
BMJ | 25 OctOBer 2008 | VOluMe 337       983
evaluations. The key message for policy makers is 
the need to consider evaluation requirements in 
the planning of new initiatives, and wherever pos-
sible to allow for an experimental or a high qual-
ity non-experimental approach to the evaluation 
of initiatives when there is uncertainty about their 
effectiveness.
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Mysterious indeed are the principles of medicine;
Flexibility of mind is a quality required.
Use eyes and ears, ask questions, take the pulses:
Omit but one and the examination’s incomplete.
First look for outward signs of the patient’s vital energy.
Dried? Smooth? Fat? Thin? Active? Does he sleep well?
Secondly, listen to whether the voice is clear or harsh:
Determine if the words he speaks are true or crazed.
Third, you must ask how long disease has lasted,
And how the patient eats, drinks, and relieves himself.
Fourth, feel the pulses and be clear about the veins:
Are they deep, shallow, external or inside?
Should I not look and listen, ask questions and take the 
pulses,
Never in all his days will the king be well again.
Journey to the West by Wu Cheng’en (1500-1582)
Submitted by Stanislav Baltsezak, general practitioner, International SOS 
Clinic, Nanjing, China
Endpiece
Mysterious indeed are the principles of medicine
